title: Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.
abstract: Medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia are frequently associated with changes in sexual function. While these medications are generally well-tolerated and have both reduced and delayed more invasive surgical options, the ramifications of long-term chronic use are largely unknown. Sexual side effects of these medications are frequently either reported as part of a short-term initial drug study or have inflexible endpoints that are not able to gauge more subtle changes in sexual performance. This review will delineate the currently known effects of these medications on sexual function and will consider mechanisms of dysfunction.
authors.affiliation: Albany Medical College, Albany, NY, 12208, USA, chuck.welliver@gmail.com.
authors.forename: Charles
authors.initials: C
authors.lastname: Welliver
authors.forename: Michael
authors.initials: M
authors.lastname: Butcher
authors.forename: Yogitha
authors.initials: Y
authors.lastname: Potini
authors.forename: Kevin T
authors.initials: KT
authors.lastname: McVary
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000009:adverse effects*; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D053448:Prostatism / Q000188:drug therapy* / Q000209:etiology; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists